<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103024</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457C2302E1</org_study_id>
    <secondary_id>2009-015509-38</secondary_id>
    <nct_id>NCT01103024</nct_id>
  </id_info>
  <brief_title>Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis</brief_title>
  <acronym>INSURE</acronym>
  <official_title>A 34-week Extension to a 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior, or Panuveitis Requiring Immunosuppression (INSURE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of the extension study is to provide patients completing the 28-week core study
      with an opportunity to receive an additional 22 weeks of continuous treatment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Core study in non-infectious active uveitis was terminated. Patients came only for the planned
    safety follow-up visit in this extension study.
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of recurrence</measure>
    <time_frame>baseline to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in immunosuppressive medication score from core study baseline</measure>
    <time_frame>baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence after the initial induction of quiescence (≤ 0.5+ anterior chamber cell grade and ≤ 0.5+ vitreous haze grade) by study treatment or rescue medication</measure>
    <time_frame>baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in best corrected visual acuity from baseline</measure>
    <time_frame>baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Quality of Life/Patient reported outcome assessments</measure>
    <time_frame>baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in vitreous haze grade and anterior chamber cell grade from baseline to 52 weeks</measure>
    <time_frame>baseline to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>AIN457 300mg s.c every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 300mg s.c every 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 150mg s.c every 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo s.c every 2 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AIN457</intervention_name>
    <arm_group_label>AIN457 300mg s.c every 2 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AIN457</intervention_name>
    <arm_group_label>AIN457 300mg s.c every 4 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AIN457</intervention_name>
    <arm_group_label>AIN457 150mg s.c every 4 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo s.c every 2 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have completed the entire treatment period of the 28-week core study

          -  Patients must be able to understand and communicate with the investigator and comply
             with the requirements for the study and must give a written, signed, and dated
             informed consent before study treatment in the extension study

        Exclusion Criteria:

          -  Inability or unwillingness to undergo repeated subcutaneous injections

          -  Inability to comply with study or follow-up procedures

          -  Any medical or psychiatric condition which, in the investigator's opinion would
             preclude the participant from adhering to the protocol or completing the study per
             protocol

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test (&gt; 5 mIU/mL)

          -  Women of childbearing potential (WoCBP), defined as all women physiologically capable
             of becoming pregnant, UNLESS

          -  They are using simultaneously double barrier or two acceptable methods of
             contraception

          -  They are postmenopausal with an appropriate clinical profile and had no regular
             menstrual bleeding for at least twelve (12) months prior to initial dosing

          -  They have undergone reliable surgical sterilization at least six (6) months prior to
             initial dosing

          -  Their career, lifestyle, or sexual orientation precludes intercourse with a male
             partner

          -  Partners have been sterilized by vasectomy or other reliable means

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Kyoto</city>
        <zip>602-0841</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tochigi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <disposition_first_submitted>May 2, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 2, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 4, 2012</disposition_first_posted>
  <last_update_submitted>May 2, 2012</last_update_submitted>
  <last_update_submitted_qc>May 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Active uveitis</keyword>
  <keyword>intermediate uveitis</keyword>
  <keyword>panuveitis</keyword>
  <keyword>posterior uveitis</keyword>
  <keyword>uveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

